Literature DB >> 31602365

Plasma Beta-Glucuronidase Activity: A Novel Tool to Distinguish Type 1 from Type 2 Amiodarone-Induced Thyrotoxicosis?

Georgios K Markantes1, Marina A Michalaki1, George A Vagenakis2, Fotini N Lamari3, Efthymia Pitsi3, Maria Eliopoulou4, Nicholas G Beratis5, Kostas B Markou1.   

Abstract

BACKGROUND: Amiodarone-induced thyrotoxicosis (AIT) is a common and deleterious side effect of amiodarone use. There are two types of AIT, characterized by distinct pathogenic mechanisms and, hence, different treatments. Discriminating between type 1 (AIT1) and type 2 (AIT2) AIT is often very challenging. Beta-glucuronidase (β-G) is a lysosomal enzyme released into the extracellular fluid during inflammation.
OBJECTIVES: To examine whether the determination of the plasma activity of β-G is useful in distinguishing AIT1 from AIT2.
METHODS: The study included 67 subjects: 9 with AIT1, 9 with AIT2, 14 with hyperthyroidism due to Grave's disease or toxic multinodular goiter, 14 with subacute thyroiditis, and 21 euthyroid controls. Thyroid function tests and plasma β-G activity were determined in all participants, while thyrotoxic patients also underwent thyroid ultrasound/scintigraphy and urine iodine excretion assessment.
RESULTS: Plasma β-G activity (expressed as mean ± SD in nmol 4-methylumbelliferone [4-MU]/mL plasma/h) in AIT2 was higher compared to AIT1 (2,263.6 ± 771 vs. 1,101.8 ± 201.9, p < 0.05) and similar to subacute thyroiditis (2,263.6 ± 771 vs. 2,083.2 ± 987.5, p = ns). β-G activity did not differ significantly between AIT1 and controls (1,101.8 ± 201.9 vs. 954.6 ± 248.6, p = ns). ROC curve analysis revealed that β-G activity had a high predictive value for destructive processes, namely AIT2 and subacute thyroiditis (AUC 0.846, 95% CI 0.748-0.943) and a cut-off value of 1,480.5 nmol 4-MU/mL plasma/h was able to discriminate between destructive and non-destructive thyroid conditions with 74% sensitivity and 82% specificity.
CONCLUSION: In our study, plasma β-G activity performed well in distinguishing AIT1 from AIT2. Further studies are warranted to establish its usefulness as a discriminator between the two AIT types.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  Amiodarone-induced thyrotoxicosis; Beta-glucuronidase; Destructive thyroiditis; Plasma beta-glucuronidase activity

Year:  2019        PMID: 31602365      PMCID: PMC6738219          DOI: 10.1159/000500355

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN: 2235-0640


  27 in total

Review 1.  The effects of amiodarone on the thyroid.

Authors:  E Martino; L Bartalena; F Bogazzi; L E Braverman
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

2.  The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis.

Authors:  L Tomisti; C Urbani; G Rossi; F Latrofa; C Sardella; L Manetti; I Lupi; C Marcocci; L Bartalena; O Curzio; E Martino; F Bogazzi
Journal:  J Endocrinol Invest       Date:  2016-01-13       Impact factor: 4.256

3.  The fluorimetric estimation of beta-glucuronidase in blood plasma.

Authors:  J W Woollen; P G Walker
Journal:  Clin Chim Acta       Date:  1965-12       Impact factor: 3.786

Review 4.  Amiodarone and thyroid.

Authors:  Silvia A Eskes; Wilmar M Wiersinga
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-12       Impact factor: 4.690

5.  Release of lysosomal enzyme beta-glucuronidase from isolated human eosinophils.

Authors:  T Marshall; P Shult; W W Busse
Journal:  J Allergy Clin Immunol       Date:  1988-10       Impact factor: 10.793

6.  A pseudodeficiency allele (D152N) of the human beta-glucuronidase gene.

Authors:  R Vervoort; M R Islam; W Sly; A Chabas; R Wevers; J de Jong; I Liebaers; W Lissens
Journal:  Am J Hum Genet       Date:  1995-10       Impact factor: 11.025

Review 7.  Consequences of excess iodine.

Authors:  Angela M Leung; Lewis E Braverman
Journal:  Nat Rev Endocrinol       Date:  2013-12-17       Impact factor: 43.330

8.  Beta-glucuronidase in the diagnosis of bacterial meningitis and response to treatment.

Authors:  N G Beratis; M I Eliopoulou; G A Syrogiannopoulos
Journal:  Acta Paediatr       Date:  2003-11       Impact factor: 2.299

9.  Effect of phenobarbital, spironolactone and pregnenolone-16 alpha-carbonitrile on rat hepatic beta-glucuronidase.

Authors:  P N Kourounakis; E Tani
Journal:  Res Commun Mol Pathol Pharmacol       Date:  1995-04

Review 10.  Update on clinical and research application of fecal biomarkers for gastrointestinal diseases.

Authors:  Imran Siddiqui; Hafsa Majid; Shahab Abid
Journal:  World J Gastrointest Pharmacol Ther       Date:  2017-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.